Log in

ASX:OPTOpthea Stock Price, Forecast & News

A$2.87
-0.03 (-1.03 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$2.79
Now: A$2.87
A$2.96
50-Day Range
A$2.15
MA: A$2.58
A$3.02
52-Week Range
A$0.57
Now: A$2.87
A$4.15
Volume504,572 shs
Average VolumeN/A
Market Capitalization$772.48 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.65 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9826 0399

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$152,584.00
Cash FlowA$0.28 per share
Book ValueA$0.27 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$772.48 million
Next Earnings DateN/A
OptionableNot Optionable

Receive OPT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter.

Opthea (ASX:OPT) Frequently Asked Questions

How has Opthea's stock been impacted by COVID-19 (Coronavirus)?

Opthea's stock was trading at A$2.62 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OPT stock has increased by 9.5% and is now trading at A$2.87. View which stocks have been most impacted by Coronavirus.

How were Opthea's earnings last quarter?

Opthea Ltd (ASX:OPT) released its earnings results on Friday, August, 9th. The company reported ($0.09) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.09) by $0.00. View Opthea's earnings history.

Has Opthea been receiving favorable news coverage?

News coverage about OPT stock has trended negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Opthea earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutOpthea.

Who are some of Opthea's key competitors?

Who are Opthea's key executives?

Opthea's management team includes the following people:
  • Dr. Megan Baldwin Ph.D., MAICD, MD, CEO & Exec. Director
  • Mr. Michael Tonroe, CFO & Company Sec.
  • Mr. Richard Chadwick Ph.D., Head of Intellectual Property
  • Dr. Michael Gerometta, Head of CMC Devel.
  • Dr. Ian Leitch, Director of Clinical Research

What is Opthea's stock symbol?

Opthea trades on the ASX under the ticker symbol "OPT."

What is Opthea's stock price today?

One share of OPT stock can currently be purchased for approximately A$2.87.

How big of a company is Opthea?

Opthea has a market capitalization of $772.48 million and generates $152,584.00 in revenue each year.

What is Opthea's official website?

The official website for Opthea is www.opthea.com.

How can I contact Opthea?

The company can be reached via phone at 61 3 9826 0399.

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.